Biote corp.

Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity...Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives. IRVING, Texas--(BUSINESS WIRE)--May 30, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer.biote Corp Market Cap as of today is 323 M. Compare the current Market Cap against historical performance and benchmark the BTMD Market Cap against ...

Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ...

biote Corp. 1875 West Walnut Hill Lane Suite 100 Irving, TX 75038 United States 844 604 1246 https://biote.com Sector(s) : Healthcare Industry : Medical Care Facilities Full Time Employees : 186On May 17, 2023, biote Corp., a Delaware corporation (the “Company”), held its 2023 annual meeting of stockholders (the “Annual Meeting”). Below are detailed voting results on each matter voted on which are described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and ...

IRVING, Texas--(BUSINESS WIRE)--Jun. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common stock by one its stockholders at a price of $5.35 per share.Nov 29, 2023 · When you look at biote Corp’s price-to-sales ratio at 0.83 compared to the industry median at 4.54, this company has a lower price relative to revenue compared to its peers. This could make biote Corp’s stock more attractive for value investors. Now, let’s assess biote Corp’s EV/EBITDA ratio, also known as enterprise multiple. biote Corp. is a member of the Zacks Medical - Products industry. One other stock in the same industry, InMode INMD, finished the last trading session 2.3% higher at $40.74.biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified ...

As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ...

biote Corp. 1875 W. Walnut Hill Ln #100 Irving, TX 75038 (312) 212-8079 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Ryan Sansom Peter Byrne Cooley LLP 500 Boylston Street Boston, MA 02116-3736 (617) 937-2300 Steven Burwell Proskauer Rose LLP 11 Times Square New York, NY …

IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating …Jun 8, 2023 · As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ”), the opportunity to receive 0.23 shares of Common ... Irving-based Biote, a medical practice-building business within the hormone optimization space, will be listed on Nasdaq through a business combination with Haymaker Acquisition Corp. III. Biote—which will earn projected revenue of $136 million in 2021—trains practitioners to identify and treat early indicators of hormone-related aging …First Quarter 2023 Financial Highlights, year-over-year: Revenue of $44.8 million, a 20.7% increase. Gross profit margin of 69.1%, a 220-basis point increase. Net loss of $ (21.4) million and GAAP loss per share of $ (0.39), primarily reflecting the impact of transaction-related items. Adjusted EBITDA of $13.1 million, a 12.4% increase 1.PART I . INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS . Pursuant to General Instruction E of Form S-8, biote Corp. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (i) an additional 4,498,916 shares of Class A common stock, par value $0.0001 (the …On May 26, 2022, Haymaker completed the Business Combination with Biote and changed its name to “biote Corp.”. On May 26, 2022, the Company issued a press release announcing the consummation of the Business Combination. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with ...III, a $317.5 million SPAC which successfully completed a business transaction with biote Corp. Prior and current public company board experience: Director of ...The document(s) containing the information specified in Part I will be sent or given to participants in the biote Corp. 2022 Equity Incentive Plan (the “2022 Plan”) and participants in the biote Corp. 2022 Employee Stock Purchase Plan (the “2022 ESPP” and together with the 2022 Plan, the “Plans”) as specified by Rule 428(b)(1) of ...Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2023 2022 Assets: Current assets: Cash and cash equivalents $ 65,575 $ 79,231 Short ...IRVING, Texas, October 24, 2023--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading provider of hormone optimization, today announced the Company …PDF Version. IRVING, Texas -- (BUSINESS WIRE)--Oct. 10, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical …

Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ...biote Corp stock performance at a glance. Check biote Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

IRVING, Texas-- ( BUSINESS WIRE )--biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization...Biote Corp. biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers worldwide.IRVING, Texas--(BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of …The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts.Apr 6, 2023 · Biote Corporation March 29, 2023 at 8:30 a.m. Eastern And now I'd like to turn the call over to Samar Kamdar, our Chief Financial Officer, to review our financial results. Samar Kamdar Thank you, Terry. Biote generated full year 2022 revenue and adjusted EBITDA of $165 million and $50.1 million biote Corp Market Cap as of today is 323 M. Compare the current Market Cap against historical performance and benchmark the BTMD Market Cap against ...... Biote Corp. (Nasdaq: BTMD), a leading provider of preventive health care, since 2022. Mr. Heyer also serves on the boards of directors of several private ...

Nov 29, 2023 · When you look at biote Corp’s price-to-sales ratio at 0.83 compared to the industry median at 4.54, this company has a lower price relative to revenue compared to its peers. This could make biote Corp’s stock more attractive for value investors. Now, let’s assess biote Corp’s EV/EBITDA ratio, also known as enterprise multiple.

IRVING, Texas, May 30, 2023--biote Corp. (NASDAQ: BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy ...

America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.Oct 24, 2023 ... IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today ...Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program desig ned to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …May 31, 2022 · Biote Corp. biote Corp. provides precision and preventive medicines. The Company offers hormone therapy and products that boosts energy and immune system. biote serves customers worldwide. May 30, 2023 · Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives. IRVING, Texas--(BUSINESS WIRE)--May 30, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. Full Year 2022 Highlights, year over year: Revenue of $165.0 million, an 18.3% increase. Net income of $1.3 million and fully diluted GAAP loss per share of $ (0.12) . “Biote achieved record financial results in the fourth quarter and for the full 2022 year, driven by strong growth in revenue and Adjusted EBITDA, which were at the high end of ...Nov 27, 2023 · About BTMD. biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what …Mar 1, 2021 · IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding ... Exhibit 99.1 . Biote Appoints Samar Kamdar as Chief Financial Officer . IRVING, TX, August 24, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr. Kamdar will oversee …On November 3, 2022, the Board of Directors of biote Corp. increased the size of the Board from six to seven directors and, following the recommendation of the Nominating and Corporate Governance Committee, appointed Debra L. Morris to serve as a member of the Board and as a member of the Board's Audit Committee, effective …Biote Corp. Consolidated Statements of Operations (In Thousands, except per share values) (Unaudited) Three Months Ended March 31, 2023. 2022. Revenue: Product revenue $ 44,155 $ 36,758. Service ...

Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Oct 24, 2023 · Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call. -- (BUSINESS WIRE)--Oct. 24, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on , after the close of the market. A conference ... IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ...Instagram:https://instagram. molina insurance reviewsfinance 101 classsoundhound stock newsobjective of telehealth Investor FAQs. Show All. Where is Biote's corporate headquarters? Biote’s corporate headquarters is at 1875 West Walnut Hill Lane, Suite 100 Irving, TX 75038. What is Biote’s fiscal year? best alternative to bloomberg terminalemployment history for home loan Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.IRVING, TX, December 13, 2021 — BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive … fdvv holdings Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023.. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) …Nov 14, 2023 · Description. Filing Group. View. Nov 14, 2023. 424B3. Form of prospectus reflecting facts events constituting substantive change from last form. Registration Statements. View HTML. 0000950170-23-063215.pdf.